Beijing Strong BiotechnologiesInc Gestione

Gestione criteri di controllo 3/4

Beijing Strong BiotechnologiesInc Il CEO è Xi Liu, nominato in Mar2011, ha un mandato di 13.67 anni. possiede direttamente 11.48% delle azioni della società, per un valore di CN¥ 963.66M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 13.7 anni e 5.9 anni.

Informazioni chiave

Xi Liu

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	13.7yrs
Proprietà del CEO	11.5%
Durata media del management	13.7yrs
Durata media del Consiglio di amministrazione	5.9yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Xi Liu (62 yo)

13.7yrs

Mandato

CN¥2,434,400

Compensazione

Mr. Xi Liu has been General Manager and Non-Independent Director of Beijing Strong Biotechnologies, Inc. since March 2011. Mr. Liu holds Ph.D.

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Xi Liu	GM & Non-Independent Director	13.7yrs	CN¥2.43m	11.48% CN¥ 963.7m
Wei Liu	CFO & Accounting Supervisor	13.7yrs	CN¥574.90k	0.027% CN¥ 2.2m
Sheng Dan	Deputy GM & Non-Independent Director	no data	CN¥1.81m	0.061% CN¥ 5.1m
Jian Min Wang	Secretary of the Board of Directors	9.4yrs	CN¥472.80k	0.071% CN¥ 6.0m
Qinghai Yang	Deputy General Manager	no data	Nessun dato	0.048% CN¥ 4.0m
Qixin Lin	Deputy General Manager	no data	Nessun dato	0.054% CN¥ 4.5m

13.7yrs

Durata media

47.5yo

Età media

Gestione esperta: Il team dirigenziale di 300406 è esperto e expertise (durata media dell'incarico 13.7 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Xi Liu	GM & Non-Independent Director	13.7yrs	CN¥2.43m	11.48% CN¥ 963.7m
Sheng Dan	Deputy GM & Non-Independent Director	4.3yrs	CN¥1.81m	0.061% CN¥ 5.1m
Zuojun Zou	Chairman of the Board	13.7yrs	CN¥2.43m	6.73% CN¥ 564.9m
Xiaolin Sun	Non-Independent Director	13.7yrs	Nessun dato	8.63% CN¥ 724.6m
Aiping Luo	Non-Independent Director	13.7yrs	Nessun dato	9.76% CN¥ 819.3m
Tao Jiang	Chairman of the Supervisory Committee	7.6yrs	CN¥84.00k	Nessun dato
Jian Ding	Independent Director	no data	CN¥84.00k	Nessun dato
Lei Fu	Independent Director	no data	CN¥84.00k	Nessun dato
Yonghong Chen	Independent Director	4.3yrs	CN¥84.00k	Nessun dato
Hongjun Liang	Non-Independent Director	4.3yrs	Nessun dato	Nessun dato
Xiaoya Wang	Non-Independent Director	1.2yrs	Nessun dato	0.080% CN¥ 6.7m
Jianping Yang	Independent Director	1.2yrs	Nessun dato	Nessun dato

5.9yrs

Durata media

62yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 300406 sono considerati esperti (durata media dell'incarico 5.9 anni).

Beijing Strong BiotechnologiesInc Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Beijing Strong Biotechnologies,Inc., Annual General Meeting, Apr 22, 2024

Beijing Strong Biotechnologies,Inc. Approves Executive Appointments

Insufficient new directors

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.20 (vs CN¥0.22 in 3Q 2023)

Investor sentiment deteriorates as stock falls 16%

Beijing Strong Biotechnologies,Inc. to Report Q3, 2024 Results on Oct 25, 2024

Investor sentiment improves as stock rises 18%

Second quarter 2024 earnings released: EPS: CN¥0.22 (vs CN¥0.22 in 2Q 2023)

Beijing Strong Biotechnologies,Inc. to Report First Half, 2024 Results on Aug 23, 2024

First quarter 2024 earnings released: EPS: CN¥0.21 (vs CN¥0.19 in 1Q 2023)

Upcoming dividend of CN¥0.20 per share

Beijing Strong Biotechnologies,Inc. Announces Final Cash Dividend (Tax Included) (A Shares) for 2023, Payable on 07 May 2024

Full year 2023 earnings released: EPS: CN¥0.90 (vs CN¥0.67 in FY 2022)

Beijing Strong Biotechnologies,Inc., Annual General Meeting, Apr 22, 2024

Investor sentiment improves as stock rises 15%

New minor risk - Share price stability

Beijing Strong Biotechnologies,Inc. to Report Fiscal Year 2023 Results on Mar 30, 2024

Third quarter 2023 earnings released: EPS: CN¥0.22 (vs CN¥0.18 in 3Q 2022)

Beijing Strong Biotechnologies,Inc. to Report Q3, 2023 Results on Oct 25, 2023

Beijing Strong Biotechnologies,Inc. Approves Executive Appointments

Insufficient new directors

Second quarter 2023 earnings released: EPS: CN¥0.22 (vs CN¥0.11 in 2Q 2022)

New minor risk - Dividend sustainability

Beijing Strong Biotechnologies, Inc. (SZSE:300406) announces an Equity Buyback for CNY 80 million worth of its shares.

Beijing Strong Biotechnologies, Inc. to Report First Half, 2023 Results on Aug 10, 2023

Beijing Strong Biotechnologies, Inc. Announces Dividend on Share A for 2022, Payable on May 22, 2023

Full year 2022 earnings released: EPS: CN¥0.67 (vs CN¥0.69 in FY 2021)

Now 21% undervalued

Third quarter 2022 earnings released: EPS: CN¥0.18 (vs CN¥0.15 in 3Q 2021)

Beijing Strong Biotechnologies, Inc. (SZSE:300406) signed an Equity Transfer Agreement to acquire an additional 4.45% stake in Fuzhou Maixin Biotech. Co., Ltd. from Xinyu Yuanlang Management Consulting Partnership (Limited Partnership) for approximately CNY 130 million.

Second quarter 2022 earnings released: EPS: CN¥0.11 (vs CN¥0.19 in 2Q 2021)

Beijing Strong Biotechnologies, Inc. Announces Final Dividend on A Shares for the Year 2021, Payable on 27 May 2022

Beijing Strong Biotechnologies, Inc. Approves Cash Dividend for 2021

Beijing Strong Biotechnologies, Inc. Announces Final Cash Dividend Proposal for 2021

Full year 2021 earnings released: EPS: CN¥0.69 (vs CN¥0.21 in FY 2020)

Beijing Strong Biotechnologies, Inc. (SZSE:300406) entered into an agreement to acquire 75% stake in Wuhan Healcare Pharmaceuticals Technology Development Co., Ltd. from Xia Zhihui and Wang Ying for CNY 4 million.

Investor sentiment improved over the past week

Beijing Strong Biotechnologies, Inc. (SZSE:300406) announces an Equity Buyback for CNY 100 million worth of its shares.

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.15 (vs CN¥0.10 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.19 (vs CN¥0.039 in 2Q 2020)

Beijing Strong Biotechnologies, Inc. Announces Final Cash Dividend for 2020, Payable on 27 May 2021

Full year 2020 earnings released: EPS CN¥0.21 (vs CN¥0.66 in FY 2019)

Full year 2020 earnings released: EPS CN¥0.21 (vs CN¥0.66 in FY 2019)

New 90-day low: CN¥20.29

Beijing Strong Biotechnologies, Inc. to Report Fiscal Year 2020 Results on Mar 26, 2021

New 90-day high: CN¥23.45

Third quarter earnings released

New 90-day low - CN¥19.38

First half earnings released

Beijing Strong Biotechnologies, Inc. to Report First Half, 2020 Results on Aug 28, 2020

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media